June 2018 - Wakunaga of America

What do Kyolic® AGE™ Blood Pressure Studies Mean for You?

For over 20 years, Kyolic Aged Garlic Extract (AGE) has been the subject of clinical studies regarding its effects on lowering blood pressure. Most recently, Dr. Karen Ried, the Director of Research of the National Institute of Integrative Medicine in Australia, completed three studies that show significant reduction in systolic blood pressure readings in patients with hypertension, after only 12 weeks.1,2,3

The ability of Kyolic AGE to document positive results in lowering blood pressure levels in study after study, gives hypertensive patients a clinically proven, natural alternative to other medications that may have negative side effects for them. For anyone with a history of hypertension in their family, Kyolic AGE is an important consideration as a daily supplement for maintaining healthy blood pressure levels.

Dr. Ried’s studies were conducted as double-blind, randomized, placebo-controlled trials of 12 weeks with various dosages of Kyolic AGE. In the US, Kyolic AGE is available in liquid or pill format in daily dosages of 1000-1200 mg. Talk to your healthcare professional about what products and lifestyle changes are right for you in your fight to lower high blood pressure and lead a more health-filled life.

Product recommendation: Kyolic 109 Blood Pressure – Aged Garlic Extract plus added benefits from Nattokinase and L-Theanine.

Blood Pressure Lowering Effects Clinical Studies Recap

  1. Cicero AF, Colletti A. 2015. High Blood Press Cardiovasc Prev.

“In particular, a relatively large body of evidence supports the use of nutraceuticals, including AGE, with possible blood pressure lowering effect.”

  1. Steiner M, Khan AH, et al. 1996. Shinyaku to Rinsho (Jpn J New Remedies Clin). 45(3):456-66.

Compared to baseline values, significant reductions in both systolic and diastolic blood pressure (9% decreases for both) were noted in this double-blind, crossover study. Hyperlipidemic patients that were consuming the National Cholesterol Education Program (NCEP) Step I diet given placebo for 6 months and followed by AGE for 4 months showed the most significant results.

  1. Steiner M, Khan AH, et al. 1996. Am J Clin Nutr. 64(6):866-70.

Another double-blind, placebo-controlled crossover study of hyperlipidemic patients (with cholesterol levels of 220-290 mg/dL) on the National Cholesterol Education Program (NCEP) Step I diet showed a 5.5% decrease in systolic blood pressure following a 6-month oral intake of AGE.

  1. Ried K, Frank OR, et al. 2010. Maturitas. 67(2):144-50.

In a parallel, randomized, double-blind, placebo-controlled study, patients with treated but uncontrolled hypertension (systolic blood pressure [SBP] ≥ 140 mm Hg or diastolic blood pressure [DBP] ≥ 90 mm Hg) were given 4 capsules of Kyolic AGE or 17 placebo daily for 12 weeks. Patients taking AGE for 12 weeks were shown to have lower systolic blood pressure, on average 10.2 ± 4.3 mm Hg (7.5%), than the control group.

  1. Ried K, Frank OR, et al. 2013. Eur J Clin Nutr. 67(1):64-70.

Patients with uncontrolled systolic hypertension (systolic blood pressure [SBP] ≥ 140 mm Hg) participated in a double-blind, randomized, placebo-controlled dose-response trial of 12 weeks. Participants were allocated to one, two or four capsules daily of Kyolic AGE or placebo. Average SBP was significantly reduced by 11.8 ± 5.4 mm Hg in the garlic-2-capsule-group over 12 weeks compared with placebo, and reached borderline significant reduction in the garlic-4-capsule-group at 8 weeks (-7.4 ± 4.1 mm Hg).

  1. Ried K, Travica N. et al. 2015. The 5th Science of Nutrition in Medicine and Healthcare Conference. Melbourne, Australia. May 2-3, 2015

Ried K, Travica N, et al. 2016. Integr Blood Press Control. 9:9-21.

Patients with uncontrolled hypertension were given 1.2 g of AGE or placebo daily in a double-blind, randomized, placebo-controlled trial of 12 weeks. Average blood pressure was significantly reduced by 5.0 ± 2.1 mmHg systolic. In addition, within this group, 58% of responders had an even better response with a reduction of 11.5 ± 1.9 mmHg systolic and 6.3 ± 1.1 mmHg diastolic compared to placebo. Central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse wave velocity and arterial stiffness tended to improve in the garlic-group more than in the placebo group. Trends in beneficial effects of garlic on tumor necrosis factor-α (TNF-α), total cholesterol, low-density lipoprotein (LDL) cholesterol and apolipoproteins were also observed.

This article is for informational purposes only. This article is not, nor is it intended to be, a substitute for professional medical advice, diagnosis, or treatment and should never be relied upon for specific medical advice.